144,465 members

Skip to content. | Skip to navigation

News

NICE draft guidance recommends pertuzumab for early treatment of breast cancer

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

NICE draft guidance recommends pertuzumab for early treatment of breast cancer

NICE has published guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes.